Caption Management’s Celldex Therapeutics CLDX Stock Holding History

Caption Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.07M	Buy	+55,700	New	+$1.8M	0.01%	896
2025 Q1	–	Sell	-7,462	Closed	-$167K	–	1592
2024 Q4	$189K	Sell	7,462 -102,538	-93%	-$2.79M	﹤0.01%	1288
2024 Q3	$3.74M	Buy	+110,000	New	+$4.19M	0.06%	373
2024 Q1	–	Sell	-39,700	Closed	-$1.63M	–	1264
2023 Q4	$1.57M	Buy	39,700 +26,700	+205%	+$785K	0.02%	679
2023 Q3	$358K	Buy	+13,000	New	+$407K	0.01%	1007
2023 Q1	–	Sell	-5,000	Closed	-$216K	–	1145
2022 Q4	$223K	Sell	5,000 -5,944	-54%	-$212K	﹤0.01%	1048
2022 Q3	$307K	Buy	+10,944	New	+$336K	﹤0.01%	1177
2022 Q1	–	Sell	-26,500	Closed	-$847K	–	1514
2021 Q4	$1.02M	Sell	26,500 -46,500	-64%	-$2.03M	0.01%	1041
2021 Q3	$3.94M	Buy	+73,000	New	+$3.43M	0.05%	539

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caption Management's CLDX Position: Q2 2026 in Review

Caption Management opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 55,700 shares worth $2.07M. The stake represents 0.01% of the portfolio and ranks #896 among its holdings. This is a return to the name: Caption Management previously reported a position in CLDX as recently as Q4 2024.

Caption Management first reported a position in CLDX in Q3 2021 and has held it in 9 quarters since. The position peaked at $3.94M in Q3 2021. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Caption Management held 55,700 shares of Celldex Therapeutics worth $2.07M as of Q2 2026.
Celldex Therapeutics was a new Caption Management position in Q2 2026.
Celldex Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #896 holding.
Caption Management first reported a position in Celldex Therapeutics in Q3 2021 and has held it in 9 quarters since.
Caption Management's Celldex Therapeutics position peaked at $3.94M in Q3 2021.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.